Lilly shares primed for rebound?: Stock analysts say 2006 may yield a rise in price out of the $50 range
Higher new-product sales, an influx of Medicare money, and improved market conditions might be just what the doctor ordered to bump Eli Lilly and Co. stock out of the funk it settled into last spring. However, as the Indianapolis company strives to meet 2006 earnings projections, analysts still see plenty to fret about, including declining sales of the company’s top-selling drug, the antipsychotic Zyprexa. Lilly shares dipped below $60 last May and spent the rest of 2005 oscillating beneath that…